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Abstract 
In this study, an effective, biocompatible and biodegradable co-polymer comprising of 
chitosan (CS) and polyvinyl alcohol (PVA) hydrogels, chemically crosslinked and 
impregnated with doxazocin, is reported.  The chemical structural properties of the 
hydrogels were evaluated by Fourier Transform Infrared spectroscopy (FTIR) and 
physical properties were analysed by scanning electron microscopy (SEM). The 
swelling behaviour is an important parameter for drug release mechanism and was 
investigated to find out the solution absorption capacity of the synthesized hydrogels. 
MTT assay revealed that doxazocin loaded hydrogels significantly hindered the cell 
viability. Flow cytometry analysis was performed to analyse the effect of 8CLH and 
4CLH on regulation of cell cycle. Moreover, in vivo anti-cancer potential of synthesized 
hydrogels was assessed by CAM Assay. Results displayed that 8CLH with 1mg/ml of 
doxazocin had prominently decreased the angiogenesis and significantly increased the 
number of cells in G1 phase of cell cycle. These results declared that 8CLH will be a 
good addition among hydrogels used for treatment of cancer by onsite delivery of drug. 
 
1. Introduction 
Cancer is a disorder usually identified by uncontrolled and vigorous proliferation 
of cells having potential to attack, spread and induces apoptosis to the nearby and 
distant cells and tissues [1]. Cancer is the prominent reason of mortality in economically 
developed countries and the second leading cause of death in developing countries [2]. 
A substantial percentage of the worldwide trouble of cancer could be averted through 
the application of prevailing cancer control knowledge [3].  
Usually, cancer is treated by surgery, radiotherapy, chemotherapy, hormonal 
therapy and immunotherapy [4, 5]. Among all, chemotherapy has been used most 
commonly to destroy cancerous cells using cytotoxic drugs. However, its use has been 
declined due to highly toxic and poorly specific drugs, insufficient availability of drugs 
to the tumour tissue, development of multi-drug resistance, and the dynamic 
heterogeneous biology of the growing tumours, hair loss, stomach irritation and poor 
number of blood cells. Due to these side effects of chemotherapy, treatments of cancer 
has been shifted from chemotherapy to localized drug release [6, 7].  
For controlled and targeted drug release, polymer-based drug delivery systems 
have been considered for many years. It includes polymer delivery vehicles, such as, 
drug-eluting films, gels, wafers, rods, and nanoparticles. It ensures bioavailability of 
drug to the specific site of disease, increased drug solubility and minimized systemic 
side effects [8-13]. 
Among polymer based drug delivery systems, polymeric hydrogels have gained 
attention as a carrier of drug to specific sites and also used in the field of tissue 
engineering, regenerative studies and biomedical sciences [14-17]. These hydrogels 
possess the potential to swell in water without dissolving [18]. Due to their high 
solution absorption capacity, sometimes their mechanical strength is compromised. To 
overcome this obstacle, cross linkers have been used to enhance the mechanical 
properties of hydrogels. Cross linkers highly affect the 3-D structure, porosity, ability 
of up taking drug solution as well as their affinity for aqueous environment [19, 20]. 
For this purpose, we have used triethyl orthoformate (TEOF) as a crosslinker. From our 
previous research experience TEOF was proved to be cyto-compatible [21] and made 
suitable hydrogels for tissue engineering and regenerative purposes [22]. 
 Chitosan, (poly-ȕ-D-glucosamine), a cationic polysaccharide, has been 
extensively used as biomaterials in the form of gels, fibers, membranes and in addition 
used as scaffold for tissue engineering and controlled drug delivery [23, 24]. It helps in 
wound healing and accelerates tissue repair by cell penetration and proliferation [25-
27]. It has water high binding capacity, fat binding capacity, bioactivity, 
biodegradability, nontoxicity, biocompatibility, antifungal activity and antibacterial 
property [28-31]. It has also been used in treatment and control of various types of 
cancers for  example, ovarian cancer [32], lung cancer [33], breast cancer [34], RIF-1 
fibrosarcoma [35], cervical cancer [36], cancers associated with mucin production [37].  
PVA possesses good chemical stability, film-forming ability and high 
hydrophilicity and has been extensively used in the formation of gels and membranes 
[38-40]. Moreover, PVA is biocompatible and nontoxic, and acquires minimal cell 
adhesion and protein absorption [41-44]. Combination of chitosan and PVA acquires 
good mechanical properties [45], and exhibit biodegradable, biocompatible and non-
toxic behavior [46-48]. Due to these properties CS and PVA blends have been 
employed in controlled drug delivery applications [49].    
In this study, doxazocin, which is a quinazoline EDVHGĮ1-adrenoceptor antagonists 
drug, has been employed as a potential anti-cancer agent [50]. It is most commonly 
used as an anti-hypertensive drug and the anti-cancer activity of doxazocin was 
discovered only recently [50].  
According to the research, quinazoline moiety is responsible for apoptic activity 
through Į1-adrenoceptor-independent-mechanism [51] and suppression of tumor 
vascularity [52]. Doxazocin can induce apoptosis in prostate cancer cells [53], 
endothelial and malignant cells [54], cardio-myocytes [55], cardio-myoblasts [56] 
breast cancer cells [57], bladder smooth muscle cells [58], urothelial cells [59], 
pituitary adenoma cells [60], colon cancer cells and HeLa cells [61]. Recent studies 
shows that doxazocin also behaves as anti-angiogenic agent for cancerous tumors [62]. 
In literature doxazocin was used with two biomaterials that are: carrageenan matrix 
tablets [63] and cellulose microcrystalline pellets [64].  
By keeping in mind, the advantages of onsite drug delivery and disadvantages of 
chemotherapy treatments, we aimed to synthesize a good biodegradable and 
biocompatible material which can support on-site delivery of doxazosin. In current 
research doxazocin loaded hydrogels were prepared from chitosan (CS) and poly vinyl 
alcohol (PVA) with two different concentrations of triethyl orthoformate (4% & 8%) 
used as a cross-linker . We prepared control hydrogel (without cross-linker), 4% 
crosslinked loaded with doxazocin (4CLH) and 8% crosslinked loaded with doxazocin 
(8CLH). It is proposed that synthesized hydrogels will inhibit the proliferation of 
cancerous cells by releasing doxazocin to the selected site. Drug will control the cancer 
by apoptosis of tumor cells only and later hydrogel will degrade itself without causing 
any harm. 
 
2. Materials and methods  
2.1. Materials 
Chitosan (CS) was purchased from Mian Scientific Company, Lahore, Pakistan, and 
further purified in our laboratories as previously described [65, 66] (degree of 
deacetylation (DD) 84%; MW: 87047.26 g/mol). Poly (vinyl alcohol) (PVA) (Mw: 
72,000, degree of hydrolysis 98%) was purchased from BDH chemical Ltd, Poole 
England, and hydrochloric acid (HCl) was supplied by RCI Labscan Ltd, Thailand.  
Sulfuric acid (H2SO4) was purchased from Merck (Germany). Triethyl orthoformate 
(98%) was purchased from Alfa Aesar (Germany). Glacial acetic acid (CH3COOH) was 
purchased from AnalaR BDH Laboratory supplies, UK. NaOH was purchased from 
Sigma Aldrich (Germany). Doxazocin was purchased by Empire Pharmaceuticals 
(Pvt), Lahore, Pakistan. HeLa cancer cell line MDA-MB-231 was taken to analyse anti-
cancer potential.  
2.2. Experimental procedure 
2.2.1. Preparation of triethyl orthoformate crosslinked chitosan and polyvinyl 
alcohol hydrogels  
CS (2.5% w/v) was dissolved in acetic acid (1%) solution. To achieve the homogenous 
and clear solution, it was stirred magnetically for 12 hours at room temperature. In 
another flask, PVA (10% w/v) was dissolved iQ GLVWLOOHG ZDWHU DW Û& DORQJ ZLWK
continuous magnetic stirring. After this, the two solutions were mixed together by 
taking 80:20 ratios (w/w) of CS and PVA, respectively, and was subjected to stirring 
for another 24 hours. On completion of 24 hours, the solution was poured into separate 
petri dishes and the dishes were frozen at -30ºC for 24 hours. Lyophilisation of frozen 
samples was done for next 24 hours in a freeze dryer at -40ºC. Then rehydration of 
lyophilized hydrogels was done by soaking hydrogels in distilled water which was 
followed by soaking of samples in different concentration solutions of TEOF (i.e. 4%, 
8% w/v) in the presence of sulphuric acid (17% w/v) for 24 hours. The hydrogels were 
then removed from petri dishes and treated with NaOH (12% w/v) for one hour. In the 
end, samples were washed with distilled water thrice and lyophilized again for 24 hours. 
 Figure 1: A) Schematic diagram for the preparation of chitosan and PVA hydrogels. 
B) Camera photographs of prepared 4CLH and 8CLH hydrogels. 
 
2.2.2. Loading of doxazocin 
Synthesized hydrogels were loaded with doxazocin. A solution of doxazocin was 
prepared having concentration of 1mg/ml of doxazocin in distilled water. The 
crosslinked scaffolds (7×3 cm) were placed in this solution overnight at room 
temperature. Scaffolds absorbed almost all the solution. In the end, doxazocin 
containing scaffolds were frozen at -20 ºC and finally lyophilized at -40 ºC for 24 h.  
2.3. FTIR analysis 
Structural characterization of prepared hydrogels was analysed by using Fourier 
Transform infrared (FTIR) spectroscopy, coupled with smart ATR accessory and photo 
acoustic sampling cells. Spectra were recorded within the wavelength range of 4000-
400 cm-1, with average 256 numbers of scans at 8cm-1 resolution on a Thermo-Nicolet 
6700P FTIR Spectrometer (USA).   
2.4. Scanning electron microscopy (SEM) 
The morphology of the hydrogels was assessed with the help of variable pressure 
scanning electron microscope (Tescan, Vega LMU) at 10 kV under low vacuum mode 
at 10 Pa. The images were scanned at various magnifications. The average pore 
diameter was calculated by using image processing software (Image J) by selecting 30 
random pores.  
2.5. Swelling studies 
Fluid absorption studies are of paramount importance for preliminary analysis of 
biodegradable materials because it is important factor while preparing biomaterials for 
tissue engineering applications [67]. . For this study, samples were cut to get 
approximately equal weight of 10 mg ± 2 mg. Samples were submerged in buffer 
solution of pH 1.2, 4.8 and 7.4 at 37 ºC. The samples were taken out after the intervals 
of 15 min, 1, 2, and 3 h. Every sample was tapped gently on blotting paper to remove 
excessive solution and weighed. To calculate the percentage degree of swelling, 
following formula was applied:  ܦ݁݃ݎ݁݁݋݂ܵݓ݈݈݁݅݊݃ሺ ? ሻ ൌ ൤ܯ െ ܯ݀ܯ݀ ൨ ൈ  ? ? ? 
Where M is the weight of sample after submersion in buffer solution and Md is the 
weight of sample before submersion in buffer solution, in its dry state. 
2.6. Chorioallantoic membrane (CAM) assay to investigate anti-cancer effect of 
doxazocin  
CAM assay was performed under sterilized conditions to analyze the in vivo anticancer 
effects of drug loaded Control, 4CLH and 8CLH. For this purpose, fertilized chicken 
eggs were purchased from Big Bird Group (Lahore, Pakistan) and put in humidified 
egg incubator (HHD 435) from day 0 of fertilization until day 8 at 37 °C. At day 8, a 
square window (1 cm2) was cut into the egg shell, and a 1 cm2 hydrogel piece was 
applied onto the chorionic allantoic membrane. One egg was implanted with only one 
piece of hydrogel. After implantation, shell window was resealed with parafilm (Bemis 
Flexible Packaging, USA) and fixed with adhesive tape and eggs were returned to 
incubator at 37 °C in a 55% humidified incubator until day 14. At day 14, angiogenesis 
was quantified by taking light microscope (Mitotic, China) pictures of the material on 
the CAM and the eggs were sacrificed. 
2.7. Cell Culture 
Hela cells were cultured LQ'XOEHFFR¶V0RGLILHG(DJOH0HGLXP'0(0*LEFR%5/
Rockville, IL, USA) supplemented with 10% fetal calf serum (FCS), 100 U/ml 
penicillin G sodium, 100 mg/ml streptomycin sulphate in an atmosphere of 95% 
humidified air and 5% CO2. Cells were passaged regularly and sub-cultured prior to 
treatment.  
2.8. MTT Cell Viability Assay 
Cell viability was quantified using an assay that utilizes the ability of live cells to reduce 
3-(4, 5-dimethylthiazol-2-yl)-2, 5 diphenyltetrasodium bromide (MTT) to produce a 
coloured formazan compound. Prior to cell culture, all the hydrogels (1 cm2) included 
in this study, (a) control hydrogels, (b) 4CLH and (c) 8CHL were sterilized in 70% 
ethanol for 30 min. Immediately before cell seeding, the drug loaded hydrogels were 
washed 2±3 times with PBS and pre-conditioned in DMEM medium for 20 min. Hela 
cells were seeded in 24-well cell culture plate with 5×104 cells per well with or without 
hydrogels in 1 ml medium. Cells seeded in 24-plate wells without hydrogels were used 
as a positive control, and were labelled tissue culture plate (TCP). On day 3, the medium 
was discarded and cells were washed with 1 ml PBS, 1 ml (0.5 mg/ml) MTT solution 
was added to each well and the wells were incubated at 37 oC for 3 h. The MTT solution 
was discarded and the cells (and hydrogels) were washed once with 1 ml PBS. To 
solubilize the formazan crystals 0.5 ml dimethyl sulfoxide (DMSO) was added to each 
well and the plate was kept under shaking conditions for 10±20 min. The optical density 
(OD) of the dissolved crystals was measured by using a microplate reader at 590 nm. 
The assay was set up in triplicates for each composition. % Viability is represented as 
the mean ± SD of three independent experiments. % Viability was calculated using the 
following formula:   
% Viability =  ୅ୠୱ୭୰ୠୟ୬ୡୣሺୱୟ୫୮୪ୣሻି୅ୠୱ୭୰ୠୟ୬ୡୣሺ୆୪ୟ୬୩ሻ୅ୠୱ୭୰ୠୟ୬ୡୣሺୡ୭୬୲୰୭୪ሻି୅ୠୱ୭୰ୠୟ୬ୡୣሺ୆୪ୟ୬୩ሻ  ? ? ? 
2.9. Fluorocytometric Cell Cycle Analysis  
Different phases of the cell cycle were distinguished by flow cytometry [68]. The assay 
is based on stoichiometric binding of propidium iodide to increasing amounts of DNA 
in cell cycle phases G0/G1, S, and G2/M. After doxazosin treatment, Hela cells were 
trypsinized, fixed and permeabilized using ethanol, rinsed in phosphate-buffered saline 
(PBS), and treated with RNAase to remove RNAs. DNA was then quantitatively stained 
with propidium iodide for 1 h at room temperature protected from light. Fluorescence 
was analyzed using a FACSC alibur flow cytometer (Becton Dickinson) and FlowJo 
software (Treestar, Ashland, OR, USA).  
3. Results and discussions 
3.1. Chemical structure analysis  
The FTIR spectrum of doxazocin drug was matched well with the spectra of doxazocin 
reported in literature [69]. This proved the chemical identity of the drug. 
FTIR spectroscopy analysis was performed to characterize the presence of specific 
chemical groups and possible interactions between CS, PVA and TEOF in the hydrogel 
and to analyse any chemical structural change in synthesized hydrogels after drug 
loading.  
In figure 3, all samples showed broad band in the region of 3500-3200 cm-1 that was 
attributed to NH2 and OH stretching vibrations [20, 70]. Discrete bands were observed 
around 2900 cm-1 and attributed to CH2 stretching vibrations [71]. Peaks observed 
around 1076 -1080 cm-1 were assigned to C-O-C stretching [72].  A new band was 
found around 1635-1640 cm-1 in the spectra of cross linked hydrogels due the 
interaction of CS, PVA and TEOF which resulted in the formation of (-C=N-) imine 
group [73]. This band was completely absent in the spectrum of control hydrogel. From 
figure 3, it was concluded that drug did not affect the chemical composition of 
hydrogels. 
 
Figure 3: FTIR results of PVA/chitosan/TEOF hydrogels. FTIR spectra in the spectral 
region (4000±500 cm-1) for (a) 8CLH with drug (b) 4CLH with drug (c) Control with 
drug (d) Control without drug. 
 
3.2. Evaluation of the morphology of synthesized hydrogels 
Figure 4 is showing scanning electron micrographs of control, 4CLH and 8CLH at 
different magnifications. These micrographs provided clear idea about porosity and 
morphology of the samples before and after drug loading. 
The SEM micrographs revealed highly porous structure of these hydrogels. The 
concentration of crosslinker significantly affected the pore sizes which were decreased 
with the increase in the concentration of crosslinker. Before drug loading, the mean 
pore size of control was 51.42±13.31 µm. After addition of crosslinker, the average 
pore size of 4CLH significantly decreased to 27.82±9.12 µm (p=0.0156) and that of 
8CLH was further declined to 7.729±0.31 µm (p=0.0059). Un-paired t-test was used to 
statistically analysed the data.   
It was also deduced by analysing micrographs, that interconnected porous structures of 
the scaffolds were retained even after loading of doxazosin but an increase in pore sizes 
of all synthesized hydrogels was observed. The drug was loaded using physical loading 
technique and drug loaded hydrogels were lyophilized again. This could be the reason 
behind increase in pore size, the re-lyophilisation might have merged the smaller pores 
thus giving rise to larger pores. The increased pore sizes were as 62.03±1.98 µm, 
31.96±12.95 µm and 18.40±11.78 µm for control, 4 CLH, and 8 CLH, respectively. 
Un-paired t-test showed significant difference among pore sizes of drug loaded 
hydrogels as well (p=<0.05).  
 
Figure 4: Scanning electron micrographs of hydrogels: (a) Control (b) 4CLH(c) 8CLH 
(magnification bars are given with each image) before and after drug loading. 
3.3. Estimation of solution absorption capacity of materials 
This test was performed to evaluate the solution absorption potential of synthesized 
hydrogels at different pH. Figure 5 is showing the swelling behaviour of hydrogels at 
different pH values i.e. 1.2, 4.8 and 7.4.  
At pH 1.2, 8 CLH showed maximum swelling behaviour among all three hydrogels. 
Unpaired t-test showed significant difference between control and 4CLH (p=0.0467), 
4CLH and 8CLH (p=0.0001), no significant difference was observed between control 
and 8CLH (p=0.0504). The possible reason behind maximum degree of swelling by 
8CLH was attributed to the presence of imine linkage. This imine group might get 
protonated at high acidic pH which caused increase in intermolecular hydrogen bonding 
between protonated imine group and water molecules in 8CLH. Overall, the degree of 
swelling at pH 1.2 was summarized as: 8CLH > control > 4CLH.  
At pH 4.8, the trend in degree of swelling was: Control > 8CLH > 4CLH. Unpaired t-
test showed statistically significant difference between control and 4CLH (p=0.0005), 
no significant difference between control and 8CLH (p=0.2747) and significant 
difference between 4CLH and 8CLH (p=0.0001). The trend in degree of swelling of 
synthesized hydrogels at pH 7.4 was similar to the trend at pH 4.8: Control > 8CLH > 
4CLH. Unpaired t-test showed significant difference between control and 4CLH (p = 
0.0005), strongly significant difference between control and 8CLH (p = 0.0190) and 
significant difference between 4CLH and 8CLH (p = 0.0009).  
 
 
 Figure 5: Solution absorption (%) of control, 4CLH, 8CLH. Values shown in the graph 
are means with 1 standard deviation either side of n=3 replicates. Blue =  Control, Red 
= 4 CLH, Grey = 8 CLH. 
At pH 4.8 and 7.4, control showed maximum swelling and cross-linked hydrogels 
showed relatively less degree of swelling. That fact is attributed to a more rigid network 
formed by the inter-intra polymer chain reactions due to the presence of cross-linker, 
reducing the flexibility and number of hydrophilic groups of hydrogel which is 
unfavourable to the swelling behaviour [20].  Control hydrogel showed maximum 
uptake of water because of presence of larger number of free ±NH2 and ±OH groups 
which might enhanced the intermolecular hydrogen bonding with water molecules. 
Form figure 5, it was concluded that synthesized hydrogels were pH sensitive. 
3.4. Qualitative and quantitative analysis of angiogenesis using CAM Assay 
Angiogenesis, particularly anti-angiogenesis, is an area of therapeutic interest in cancer 
treatment. Using an established chicken embryo chorioallantoic membrane (CAM) 
assay, we are reporting that doxazocin has anticancer potential and increase in cross-
linker in hydrogels helped to increase the anti-angiogenic activity of the drug loaded 
hydrogels.  
Our studies have shown that control hydrogel (without any drug) delivered normal 
angiogenesis. In 4 CLH, relatively lower number of blood vessels surrounded the 
incorporated scaffolds and very few capillaries were seen invading the scaffold. In 8 
CLH, the lowest number of blood vessels were seen in the vicinity of hydrogel and no 
capillaries were seen invading the scaffolds. The reason behind more anti-angiogenic 
potential of 8CLH was due to the high percentage of cross-linking in it, which might 
have supported more drug holding capacity. The dense porous network of 8CLH might 
also have entrapped large amount of drug inside it.  
  
Figure 6: Hydrogels on CAM (a) control (b) 4CLH (c) 8CLH. 
Results of CAM assay were found to be statistically significant by applying unpaired t-
test to the quantification data in figure 7. It showed significant difference (p=0.0132) 
between the control and 4 CLH hydrogel. Difference in the number of blood vessels 
was also statistically very significant between control and 8CLH hydrogel (p=0.0031) 
and statistically significant difference was also observed between 4CLH and 8CLH 
(p=0.1012).  
The order of anti-angiogenic activity showed by three hydrogels was as following: 
8CLH > 4CLH> control. 
 Figure 7: Quantification of blood vessels by blind scoring from images of scaffolds 
retrieved from CAM assay. 
 
3.5. Cell viability of doxazocin loaded hydrogels against human cervical cancer 
(Hela) cell line 
MTT assay was employed to investigate the anti-proliferative effects of hydrogels 
mediated doxazocin. Human cervical cancer (Hela) cell line was used for this test. Our 
results demonstrated that doxazocin loaded hydrogels vigorously hampered the cell 
viability compared to untreated control and tissue culture plate (TCP) control [74]. The 
progressive decrease in cell viability can be observed and directly co-related with the 
gradual increase in quantity of the loaded drug (Figure 8A) [75]. The lowest quantity 
of drug loaded (i.e., 0.1mg/ml) on both cross-linked (4% & 8% CLH) and non-cross 
linked hydrogels showed 80% cell viability compared to TCP control. Similarly, the 
increase in concentration of loaded drug to 0.5 mg/ml further reduced the mean cell 
viability WR70%.  Moreover, the further increase in concentration of loaded drug to 1 
mg/ml revealed robust inhibition in mean % cell viability (i.e., 60% in non-cross linked, 
50% in 4% CLH and 35% in 8% CLH).  
 
 
 
 
 
 Figure 8A: Doxazocin loaded hydrogels mediated effect on cell viability of human 
cervical cancer cell line (Hela Cell Line) determined by MTT assay on day 3. Tissue 
culture plate (TCP) control, control (hydrogels without drug), hydrogels loaded with 
0.1, 0.5 and 1 mg/ml drug. Blue bars represent hydrogels with cross linker, red (4HCL) 
& green (8HCL) show 4 and 8% cross linked hydrogels.  Data demonstrate the mean 
± SD of three independent experiments. 
 
3.6. Doxazocin loaded hydrogels causes cell cycle arrest in G1/G0 phase 
In addition to anti-proliferative response, we studied the effect of doxazocin on cell 
cycle regulation of Hela cells [76]. Cell cycle phases were analysed with flow 
cytometry (FACS) after treatment with the drug-loaded hydrogels. Our FACS (flow 
cytometry) analysis showed that the control hydrogels loaded with different 
concentrations of the drug (i.e., 0.1, 0.5 and 1mg/ml) did not show the alteration in cell 
cycle pattern (Figure 9A).  However, the 8CLH loaded with different concentrations of 
doxazosin (i.e., 0.1, 0.5 and 1 mg/ml), effectively induced an increase in number of 
cells in G1 phase (Figure 8B). The increase was directly correlated with the 
concentration of doxazosin and amount of cross-linker in hydrogel. Our findings reflect 
that the inhibition in viability and cell cycle arrest were effects of doxazocin loaded 
hydrogels. 
  
  
  
 
Figure 8B: Cell cycle arrest mediated by doxazocin loaded hydrogels, revealed by Flow 
Cytometry (FACS). Propidium Iodide florescence intensity correlates with the amount 
of cellular DNA contents. Decreased diploid DNA content reflects a reduced number 
of cells in G2/M phase after application of hydrogels (8CLH) (Lane B) loaded with 
different concentrations of doxazocin (i.e., 0.1, 0.5 & 1 mg/ml) compared with non-
cross linked hydrogels (Lane A). Data shown are representative of three independent 
experiments.     
Conclusion 
In present research chitosan/PVA based hydrogels were successfully crosslinked by 
using triethyl orthoformate and doxazocin was physically loaded into these hydrogels. 
The 8 CLH showed ability to hold higher amount of doxazocin as compare to non-
crosslinked and 4 CLH. FTIR spectroscopy confirmed that drug did not change its 
chemical structure in composite materials and SEM showed that hydrogels are porous. 
For assessment of anti-angiogenic potential of the hydrogels CAM assay was used. This 
test showed that 8CLH loaded with 1mg/ml of doxazocin was best to inhibit 
angiogenesis. To further prove the inhibitory potential of 8CLH loaded with 1mg/ml of 
drug, we performed MTT assay and flow cytometry analysis. MTT assay displayed that 
anti-proliferative effect of synthesized hydrogels was directly related to higher amount 
of cross-linker and drug and declared 8CLH best material to give least %age of viable 
cells. Flow cytometry analysis was performed to analyse the effect of synthesized 
hydrogels on cell cycle arrest. 8CLH caused significantly increase in G1 population in 
cell cycle.  
Hence, by gathering all results, it was concluded that 8CLH (1mg/ml of doxazocin) is 
the most approving hydrogel among all synthesized hydrogels for the onsite delivery 
of drug to treat cancer cells. 8CLH will find wide interest in biomedical materials 
research community for further development and for clinical applications. 
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